40523-32-8Relevant articles and documents
SET photochemistry of phthalimide anion and its reactivity with hydrogen donors
Sánchez-Sánchez, Cristobal,Pérez-Inestrosa, Ezequiel,García-Segura, Rafael,Suau, Rafael
, p. 7267 - 7274 (2002)
The investigation of the photochemistry of phthalimide anion has uncovered its exceptional reactivity with hydrogen donors such as alcohols, toluene, ethers and amines. Photoreactions can be conducted to high conversions and photoadducts are formed in high yield and with predictable regioselectivity. Exploratory studies have revealed that SET from the excited phthalimide anion to phthalimide is a thermodinamically favourable step that produces the electrophilic phthalimidyl radical and is the key step of the process.
Copper-mediated oxidative C-H/N-H activations with alkynes by removable hydrazides
Ackermann, Lutz,Gu, Linghui,Li, Bo,Ma, Wenbo,Mei, Ruhuai,Xiong, Feng,Yang, Chenrui,Zou, Liang
supporting information, p. 1591 - 1599 (2021/07/26)
The efficient copper-mediated oxidative C-H alkynylation of benzhydrazides was accomplished with terminal alkynes. Thus, a heteroaromatic removable N-2-pyridylhydrazide allowed for domino C-H/N-H functionalization. The approach featured remarkable functional group compatibility and ample substrate scope. Thereby, highly functionalized aromatic and heteroaromatic isoindolin-1-ones were accessed with high efficacy with rate-limiting C-H cleavage.
Phenylidene phenyl peptide compounds and medicinal composition and application thereof
-
Paragraph 0148-0152, (2018/11/22)
The invention provides phenylidene phenyl peptide compounds, a medicinal composition using the phenylidene phenyl peptide compounds as active components, and application thereof as monoamine oxidase B(MAO-B) inhibitors and application thereof to preparation of medicines for treating Parkinson's disease (PD). Monoamine oxidase B (MAO-B) has been proved to be closely related to the pathogenesis ofthe Parkinson's disease (PD) and is a classic target for research and development of the medicines for treating the Parkinson's disease (PD). The invention provides application of the phenylidene phenyl peptide compounds to preparation of the monoamine oxidase B (MAO-B) inhibitors. In-vitro kinase activity experiments prove that the phenylidene phenyl peptide compounds have a significant monoamineoxidase B (MAO-B) inhibiting effect.